Sentences with phrase «in immune response to the tumor»

Not exact matches

The introduction of infant formula to babies» diets changes the infants» gut microbiome, thus affecting the response of the infant immune system to pathogens.47 - 51 A greater amount of natural - killer cells, suggesting a more mature immune system, have been found in breastfed infants than in formula - fed infants.52 In addition, pH level in the stomach of breastfed children is better for the promotion of the protein - lipid α - lactalbumin (termed HAMLET), which induces apoptosislike death in tumor cells.51, in breastfed infants than in formula - fed infants.52 In addition, pH level in the stomach of breastfed children is better for the promotion of the protein - lipid α - lactalbumin (termed HAMLET), which induces apoptosislike death in tumor cells.51, in formula - fed infants.52 In addition, pH level in the stomach of breastfed children is better for the promotion of the protein - lipid α - lactalbumin (termed HAMLET), which induces apoptosislike death in tumor cells.51, In addition, pH level in the stomach of breastfed children is better for the promotion of the protein - lipid α - lactalbumin (termed HAMLET), which induces apoptosislike death in tumor cells.51, in the stomach of breastfed children is better for the promotion of the protein - lipid α - lactalbumin (termed HAMLET), which induces apoptosislike death in tumor cells.51, in tumor cells.51, 53

An immune response, triggered by foreign neural stem cells, could actually help attack tumors, says Evan Snyder, a stem cell biologist at Sanford Burnham Prebys Medical Discovery Institute in San Diego, California, and one of the early pioneers of the idea of using stem cells to attack tumors.

«This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response,» said Dr. Balachandran, a member of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, and corresponding author of the companion study in Nature.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapieIn addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapiein cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

C. novyi is really a two - pronged weapon against cancer: It germinates in tumors and releases cancer - killing enzymes, and it may also trigger an immune response similar to Coley's Toxin.

«It suggests there's a common mechanism in both species for susceptibility to tumor progression that may involve subversion of the host immune response.

The personalized vaccine is made from patients» own immune cells, which are exposed in the laboratory to the contents of the patients» tumor cells, and then injected into the patients to initiate a wider immune response.

The team also compared the animals» responses to the therapy's effects in laboratory cell samples and found that in vitro studies did not predict how well the viral therapy and immune response would fight tumor cells in vivo.

«The effective immune response didn't happen in every tumor model we tested, so we still need to figure out exactly what triggered the tumor shrinkage and how to predict which tumors will shrink in response to virotherapy,» said Leddon, who is also working toward her medical and doctoral degrees at the University of Cincinnati.

Less suppression of the immune response and less blood vessel formation in the tumor leads to less tumor growth.

Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection,» explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology PrograIn addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection,» explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology Prograin the anti-tumor immune cells of patients after injection,» explained Amod A. Sarnaik, M.D., assistant member of Moffitt's Cutaneous Oncology Program.

Now, scientists have modified Salmonella bacteria to trigger a particularly powerful immune response against human cancer cells implanted in mice, shrinking the tumors and — for the first time — preventing them from metastasizing.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responseTo accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responseto thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

A combination of iron - oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth - Hitchcock Norris Cotton Center researchers in the journal Nanomedicine: Nanotechnology, Biology and Medicine released online on February 24, 2014.

Mechanistic studies showed that IFN increases antitumor immune responses by enhancing antigen presentation to T cells by dendritic cells present in the tumor microenvironment.

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

The systemic response to surgery triggers the outgrowth of distant immune - controlled tumors in mouse models of dormancy

What's more, IL - 33 and the DNA vaccine augmented immunological responses in both CD4 helper T cells and CD8 killer T cells, with a large proportion of CD8 killer T cells demonstrating a further improvement in the ability of DNA vaccines to drive the immune system to kill tumor cells in animals.

For instance, a tumor influences the expression of genes in immune system cells that are involved in the body's response to cancer.

Antibodies only bind to target cells Peptide antibodies developed by Kwak and co-discoverer, Hong Qin, Ph.D., assistant professor of Lymphoma / Myeloma, wipe out MDSCs in the blood, spleen and tumor cells of mice without binding to other white blood cells or dendritic cells involved in immune response.

Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine.

While this approach has had some clinical success, in most cases, the immune response resulting from dendritic cell vaccines is short - lived and not robust enough to keep tumors at bay over the long run.

In cases where there are lots of T cells in the vicinity of a tumor, or where tumor cells have undergone large numbers of mutations, which creates additional targets for immune sentries, T cells will signal a full - fledged immune response to the canceIn cases where there are lots of T cells in the vicinity of a tumor, or where tumor cells have undergone large numbers of mutations, which creates additional targets for immune sentries, T cells will signal a full - fledged immune response to the cancein the vicinity of a tumor, or where tumor cells have undergone large numbers of mutations, which creates additional targets for immune sentries, T cells will signal a full - fledged immune response to the cancer.

The Johns Hopkins team tested ImmunoMap's ability to correlate immune responses on receptor sequencing data from T - cells in the tumors of 34 patients with cancer enrolled in a nationwide clinical trial of the immunotherapy drug nivolumab.

Oncologists have long known that in rare cases, after patients receive radiation therapy to shrink a tumor, the immune system will mount an aggressive response that wipes out not only the tumor, but metastases throughout the body that hadn't been treated with the radiation.

They used the gene - editing CRISPR / Cas9 technique to sift the genomes of melanoma cells for changes that made tumors resistant to being killed by immune T cells, which are the main actors in the immune system response against infections and cancer cells.

During inflammatory responses due to infection, trauma, or cancer, the body's immune system becomes highly activated in an attempt to fend off invading organisms, foreign bodies, or tumor cells.

Each of these molecules plays a critical role in enhancing the overall immune response to the tumor.

These types of engineered tumors are much more difficult to treat than human tumors implanted in mice, because they suppress the immune response against them.

Last year, Wittrup showed that delivering antibodies and IL - 2, a signaling molecule that helps to boost immune responses, could halt the growth of aggressive melanoma tumors in mice for as long as the treatment was given.

In 2008, he joined the group of Caetano Reis e Sousa at the Cancer Research UK (CRUK) London Research Institute and later joined the Francis Crick Institute, where he was awarded Marie Curie and EMBO long - term postdoctoral fellowships to investigate innate immune receptors and signaling pathways that trigger dendritic cell activation and drive T - cell responses against viruses or tumors.

In experiments in animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cellIn experiments in animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cellin animals, researchers from the University of Michigan Medical School showed that adding rapamycin to an immunotherapy approach strengthened the immune response against brain tumor cells.

This did induce an immune response but only led to tumor rejection in one - quarter of the animals.»

These latter two cell types can mount effective immune responses to viruses and tumors; whereas, exhausted T cells fail and memory T cells, in particular, for long - lasting durable effects.

For nearly 20 years, doctors have used cyclosporine to dull the immune response, which would otherwise reject a transplant — a strategy that carries with it a 100-fold increase in tumor risk among these patients compared to healthy individuals.

By analyzing a dataset of human immune cells stimulated with interferon — a signaling protein created in response to pathogens or tumor cells — the team could precisely identify which genes were switched on in each of 13 responding cell types.

A T - cell marker panel that can identify subsets of tumor - associated T - cells allows scientists to identify and target subpopulations of T - cells playing unique roles in the immune response against a tumor.

«Our results clearly demonstrate a significant, although unexpected, role for specific gut bacteria in enhancing the immune system's response to melanoma and possibly many other tumor types,» said study director Thomas Gajewski, MD, PhD, professor of medicine and pathology at the University of Chicago.

A personal cancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

We are particularly interested in leverage our interdisciplinary expertise in polymer chemistry, nanomedicine, drug delivery and immunobiology to innovate new approaches to modulate the tumor microenvironment and enhance cellular immune responses to cancer vaccines.

We chose this model because 1) it more closely recapitulates features of human pancreatic cancer than do s.c. - implanted tumors, 2) it can be used in immunocompetent mice to permit assessment of immune responses, and 3) the cells grow in vivo with predictable kinetics (34).

Our PDX models and other next - generation cancer modeling platforms allow you to address critical questions in oncology research, such as unexplained drug resistance, drug efficacy, genomic heterogeneity in solid tumor, and the role of the immune system in drug response.

Dr. Levitsky: My organization within Roche, Pharma Research and Early Development (pRED), has invested in antibody engineering, not only for use of monoclonal antibodies in the established ways of delivering cell - killing agents to tumors or interrupting cell signalling pathways, but also as ways to engage and manipulate the immune system's response to tumors.

Melanoma is a tumor that is recognized by the immunological system and mechanisms leading to an anti-tumor immune response of potential value in the adjuvant setting.

The researchers tested whether stromal tumor infiltrating lymphocytes (TILs) and other immune cells might predict responses to therapy in a set of 30 HER2 - positive breast cancer tissues treated with TCHP (26 patients) or with TCH without pertuzumab (4 patients).